Suscriptores   Asóciese  
Textos Completos Autorizados
EL USO DE LA TRH DISMINUYE LA OXIDACION LIPIDICA Y DE ADN EN MUJERES POSMENOPAUSICAS

v-estudie-lo-mejor.gif
Expertos Invitados





EL USO DE LA TRH DISMINUYE LA OXIDACION LIPIDICA Y DE ADN EN MUJERES POSMENOPAUSICAS

(especial para SIIC © Derechos reservados)
La etapa posmenopaúsica de la mujer se asocia con un perfil oxidativo desfavorable. En este estudio concluimos que la terapia de reemplazo hormonal no tiene ningún efecto nocivo sobre el perfil oxidativo y más bien disminuye la oxidación del ADN y de los lípidos, lo cual puede tener efecto en la salud cardiovascular y el proceso de envejecimiento en sí.
Autor:
Carlos Alberto Escalante Gómez
Columnista Experto de SIIC

Institución:
Departamento Ginecología, Hospital San Juan De Dios. Universidad De Costa Rica

Artículos publicados por Carlos Alberto Escalante Gómez
Coautor
Carlos Alberto Escalante Gómez* 
Médico, Departamento Ginecología, Hospital San Juan De Dios. Universidad De Costa Rica, San Jose, Costa Rica*
Aprobación
15 de Abril, 2013 		Primera edición
17 de Abril, 2013 		Segunda edición, ampliada y corregida
11 de Enero, 2024

EL USO DE LA TRH DISMINUYE LA OXIDACION LIPIDICA Y DE ADN EN MUJERES POSMENOPAUSICAS


Artículo completo
(castellano)
Extensión:  +/-3.47 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes
Clasificación en siicsalud
Artículos originales > Expertos de Iberoamérica >
página   www.siicsalud.com/des/expertocompleto.php/

Especialidades
Principal: Farmacología, Obstetricia y Ginecología
Relacionadas: Bioquímica, Cardiología, Diagnóstico por Laboratorio, Endocrinología y Metabolismo, Geriatría



Comprar este artículo
Extensión: 3.47 páginas impresas en papel A4

file05.gif (1491 bytes) Artículos seleccionados para su compra



Enviar correspondencia a:
C Escalante Gomez, Department of Gynecology, Hospital San Juan de Dios Universidad de Costa Rica, San José, Costa Rica
Bibliografía del artículo
1. Blokhina O, Virolainen E, Fagerstedt KV. Antioxidants, oxidative damage and oxygen deprivation stress: a review. Ann Bot (Lond) 91:179-94, 2003.
2. Scandalios JG. Oxidative stress: molecular perception and trans- duction of signals triggering antioxidant gene defensas. Braz J Med Res 38:995-1014, 2005.
3. Young IS, Woodside JV. Antioxidants in health and disease. J Clin Pathol 54:176-86, 2001.
4. Halliwell B, Gutteridge JMC, eds. Antioxidant defenses. In Free Radicals in Biology and Medicine , 3rd ed. New York: Oxford University Press; 1998.
5. Willcox J, Ash S, Catignani G. Antioxidants and prevention of chronic disease. Crit Rev Food Sci Nutr 44:275-95, 2004.
6. Tribble DL, Frank E. Dietary antioxidants, cancer and atherosclerotic heart disease. West J Med 161:605-12, 1994.
7. Ortiz A, Vargas R, Muñóz G. Incidencia y mortalidad del cáncer en Costa Rica. Costa Rica: Kamelot Comunicació n y Arte; 2005.
8. Stocker R, Keaney J. Role of oxidative modiffications in atherosclerosis. Physiol Rev 84:1381-478, 2004.
9. Heinecke J. Oxidants and antioxidants in the pathogenesis of atherosclerosis: implications for the oxidized low density lipoprotein hypothesis. Atherosclerosis 141:1-15, 1998.
10. Salonen T, Yla-Herttulal S, Yamamoto R. Autoantibodies against oxidized LDL and progression of carotid atherosclerosis. Lancet 339:883-7, 1992.
11. Gey KF, Puska P, Jordan P, Moser UK. Inverse correlation between plasma vitamin E and mortality from ischemic heart disease in cross-cultural epidemiology. ACJN 53:326-34S, 1991.
12. Stampfer MJ, Hennekens CH, Manson J, Colditz G, Rosner B, Willett W. Vitamin E consumption and risk of coronary disease in women. N Engl J Med 328:1444-9, 1993.
13. Stephens NG, Parsons A, Schoeld PM, et al. Randomized controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 347:781-6, 1996.
14. Yusuf S. Vitamin E supplementation and cardiovascular events in high risk patients. N Engl J Med 354:1917-18, 2000.
15. Ebell MH. Efficacy of antioxidants in GI cancer prevention. Am Fam Physician 71:465-6, 2005.
16. Salaganik RL. The beneffits and hazards of antioxidants: controlling apoptosis and other protective mechanisms in cancer patients and the human population. J Am Coll Nutr 20(Suppl):464-75S, 2001.
17. Lamson DW, Brignall MS. Antioxidants and cancer. 3. Quercetin. Altern Med Rev 5:304-29, 2000.
18. Christen Y. Oxidative stress in Alzheimer' s disease. Am J Clin Nutr 71:621-9S, 2000.
19. Smith MA, Perry G, Richery PL. Oxidative damage in Alzheimer' s disease. Nature 382:120-1, 1996.
20. Age-related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E and beta carotene for age related cataract and vision loss: AREDS report Nº 9. Arch Ophthalmol 119:1439-52, 2001.
21. Ehret A, Westendorp MO, Herr I, et al. Resistance of chimpanzee T cells to human virus type 1 Tat-enhanced oxidative stress and apoptosis. J Virol 70:6502-7, 1996.
22. Strehlow K, Rotter S, Wassmann S, et al. Modulation of antioxidant lipid expression and function by estrogen . Circ Res 93:170-7, 2003.
23. Unfer T, Conterato M, da Silva J, Duarte M, Emanuelli T. Inffluence of hormonal replacement therapy on blood antioxidant enzymes in menopausal women. Clin Chem Acta 369:73-7, 2006.
24. Signorelli S, Neri S, Sciacchitano S, DiPino L, Costa M, Marchese G. Behaviour of some indicators of oxidative stress in postmenopausal and fertile women. Maturitas 53:77-82, 2006.
25. Lippert TH, Seeger H, Mueck A. Clinical and pharmacological characteristics of the conjugated equine estrogens. Is their use in postmenopausal hormone replacement therapy still up to date? Arnzneimitteltherapie 17:362-4, 1999.
26. O 'C onnell MB. Pharmacokinetic and pharmacologic variation between different estrogen products. J Clin Pharmacol 35(Suppl):18-24S, 1995.
27. Bhavanani BR. Pharmacokinetics and pharmacodynamics of con- jugated equine estrogens: chemistry and metabolism. Proc Soc Exp Biol Med 217:6-16, 1998.
28. Lippert TH, Seeger H, Mueck A. Pharmocodynamics and toxi- cology of different estrogens. Hormone replacement in post- menopausal women: are all estrogens equal? Gynecol Endocrinol 15:26-33, 2001.
29. Ayres S, Abplanalp W, Liu J, Ravi T. Mechanisms involved in the protective effect of estradiol-17beta on lipid peroxidation and DNA damage. Am J Physiol 274:E1002-8, 1997.
30. Subbiah MT, Kessel B, Agrawal M, Rajan R, Abplanalp W, Rymaszewski Z. Antioxidant potential of speciffic estrogens on lipid peroxidation. J Clin Endocrinol Metab 77:1095-7, 1993.
31. Taniguchi S, Yanase T, Kobayashi K, et al. Catechol estrogens are more potent antioxidants than estrogens for the Cu(2) catalyzed oxidation of low or high density lipoprotein: anti- oxidative effects of steroids on lipoproteins. Endocr J 41:605-11, 1994.
32. Ke R, Todd D, Ahokas R. Effect of short-term hormone therapy on oxidative stress and endothelial function in African American and Caucasian postmenopausal women. Fertil Steril 79:1118-22, 2003.
33. Bednarek-Tupikowska G, Tupikowski K, Bidzinska B, et al. Serum lipid peroxides and total antioxidant status in postmenopausal women on hormone replacement therapy. Gynecol Endocinol 19:57-63, 2004.
34. Halliwell B, Grootveld M. The measurement of free radical reac- tions in humans. Some thoughts for future experimentation. FEBS Lett 213:9-14, 1987.
35. Yagi K. Simple assay for the level of total lipid peroxides in serum or plasma. Methods Molec Biol 108:101-6, 1998.
36. Armstrong D, Browne R. The analysis of free radicals, lipid per- oxides, antioxidant enzymes and compounds to oxidative stress as applied to the clinical chemistry laboratory. Adv Exp Med Biol 366:43-58, 1994.
37. Stadtman ER, Oliver CN. Metal-catalyzed oxidation of proteins. Physiological consequences. J Biol Chem 266:2005-8, 1991.
38. Kampa M, Nistikaki A, Tsaousis V. A new automated method for the determination of the total antioxidant capacity (TAC) of human plasma, based on the crocin bleaching assay. BMC Clin Pathol 2:3-18, 2002.
39. Beckman KB, Arnes B. Oxidative decay of DNA. J Biol Chem 272:19633-6, 1997.
40. Espeland M, Hogan P, Fineberg S, et al. Effects of postmenopausal therapy on glucose and insulin concentration. Diabetes Care 21:189-95, 1998.
41. Kanaya A, Herrington D, Vittinghoff E, et al. Glycemic effects of postmenopausal hormone therapy: The Heart and Estrogen/progestin Replacement Study. Ann Intern Med 138:1-9, 2003.
42. Liu S, Le May C, Wong MP, et al. Importance of extranuclear estrogen receptor-alpha and membrane G protein-coupled estrogen receptor in pancreatic islet survival. Diabetes 58:2292-302, 2009.
43. Friday K, Dong C, Fontenot R. Conjugated equine estrogen improves glycemic control and blood lipoproteins in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab 86:48-52, 2001.
44. Lamon-Fava S, Herrington DM, Horvath KV, Schaefer EJ, Asztalos BF. Effect of hormone replacement therapy on plasma lipoprotein levels and coronary atherosclerosis progression in postmenopausal women according to type 2 diabetes mellitus status. Metabolism 59:1794-800, 2010.
45. Lamon-Fava S, Herrington DM, Reboussin DM, et al. Changes in remnant and high-density lipoproteins associated with hormone therapy and progression of coronary artery disease in postmenopausal women. Atherosclerosis 205:325-30, 2009.
46. Lamon-Fava S, Posfai B, Asztalos BF, Horvath KV, Dallal GE, Schaefer E. Effects of estrogen and medroxyprogesterone acetate on subpopulations of triglyceride-rich lipoproteins and high- density lipoproteins. Metabolism 52:1330-6, 2003.
47. Arteaga E, Rojas A, Villaseca P, Bianchi M, Arteaga A, Duran D. In vitro effect of estradiol, progesterone, testosterone and of combined estradiol/progestins on low density lipoprotein oxidation in postmenopausal women. Menopause 5:16-23, 1998.
48. Ozden S, Dildar K, Hakan Y, Guilzar K. The effects of hormone replacement therapy on lipid peroxidation and antioxidant status. Maturitas 38:165-70, 2001.
49. Wen Y, Doyle M, Norris L, et al. Combined oestrogen-progesterone replacement therapy does not inhibit low-density lipoprotein oxidation in postmenopausal women. Br J Clin Pharmacol 47:315-21, 1999.
50. Naziroglu M, Simsek M, Simsek H, Aydilek N, Ozcan Z, Artilgan R. The effects of hormone replacement therapy combined with vitamins C and E on antioxidant levels and lipid profiles in postmenopausal women with type 2 diabetes. Clin Chim Acta 344:63-71, 2004.
51. Wassmann K, Wassmann S, Nickenig G. Progesterone antagonizes the vasoprotective effect of estrogen on antioxidant enzyme expression and function. Circ Res 97:1046-54, 2005.
52. Demirbag R, Yilmaz R, Erel O. The association of total antioxidant capacity with sex hormones. Scand Cardiovasc J 36:172-6, 2005.
Título español
 Bibliografía
 Artículo completo
(exclusivo a suscriptores)
 Autoevaluación
  Tema principal en SIIC Data Bases
 Especialidades

  English title
  Abstract
  Key words
Full text
(exclusivo a suscriptores)

Autor 
Artículos
Correspondencia
Patrocinio y reconocimiento
Imprimir esta página
 
 
 
 
 
 
 
 
 
 
 
 
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.
ua31618
Acerca de SIIC   Estructura de SIIC   Fuentes informativas  

Sociedad Iberoamericana de Información Científica

Copyright siicsalud© 1997-2024 ISSN siicsalud: 1667-9008
ua31517